Xcout IntelVivani Medical, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Vivani Medical, Inc. among pharmaceuticals companies — ranked by similarity to what Vivani Medical, Inc. actually does, not by market-cap band.
Subscribe to see Vivani Medical, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Vivani Medical, Inc.
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.
Vivani Medical, Inc. at a glance
Vivani Medical, Inc. is a pharmaceuticals company headquartered in Alameda, United States. It is publicly listed (VANI) with a market capitalisation of $112.8M. Xcout tracks 19 named people at Vivani Medical, Inc., including Anthony Edward Baldor (Chief Financial Officer).
Vivani Medical, Inc. leadership
- Anthony Edward BaldorChief Financial Officer
- Anthony Baldor, M.S., M.B.A.Chief Financial Officer
- Truc LeChief Operations Officer
- Lisa E. PorterChief Medical Officer
- Donald DwyerChief Business Officer & Corporate Secretary
- Don Dwyer, M.B.A.Chief Business Officer
13 more named people on record for Vivani Medical, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Vivani Medical, Inc. competitors
Ranked by semantic similarity — how close each company is to Vivani Medical, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
iRenix Medical is a private company founded in 2016 and headquartered in Palo Alto, California. The firm is engaged in the development of ophthalmic devices and drug pipelines.
Similar pharmaceuticals company
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Similar pharmaceuticals company
Kubota Pharmaceutical Holdings Co., Ltd., an international entity established in Tokyo, Japan, in 2002, focuses on the creation and advancement of a diverse range of pharmaceutical treatments and medical devices. A primary asset in their development pipeline is emixustat hydrochloride, a drug currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. Beyond its pharmaceutical endeavors, the company is also innovating in medical technology, specifically with a patient-centric ophthalmology suite designed for remote retinal monitoring. This advanced suite features both miniature, home-use optical coherence tomography (OCT) devices and high-resolution OCT technology adapted from NASA. Furthermore, Kubota Pharmaceutical Holdings is developing a wearable device aimed at controlling myopia.
Similar pharmaceuticals company
Crossject SA is an emerging specialty pharmaceutical company based in France and the U.S. that focuses on advanced regulatory and needle-free injection technologies. Headquartered in Dijon, France, the firm develops innovative drug delivery systems.
Similar pharmaceuticals company
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Similar pharmaceuticals company
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Life Sciences (Therapeutics)
MediPrint Ophthalmics is a clinical-stage eye care pharmaceutical company that develops and commercializes a proprietary ocular drug delivery portfolio. The company provides drug-eluting, comfort-enhancing contact lenses designed to offer continuous medication delivery and vision correction for patients with ocular diseases.
Biotech
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Biotechnology
Eyenovia, Inc. is a New York-based ophthalmic technology and pharmaceutical manufacturing company focused on targeted drug-delivery solutions for eye care using its proprietary Optejet device.
Healthcare
Bionic Sight is a biotechnology company founded in 2012 by Dr. Sheila Nirenberg and based in New York, New York. The firm specializes in creating neuro-prosthetic devices and developing optogenetic therapy for vision restoration.
Biotechnology
Precise Bio, Inc. is a clinical-stage regenerative medicine company that grows live organs for transplant using 3D bio-printing technology.
Health & Life Sciences
IVIVA Medical, Inc. is a subsidiary of United Therapeutics located in Woburn and Medford, Massachusetts, focused on developing bioartificial kidneys for transplants.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Vivani Medical, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Vivani Medical, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →